G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice

Oligonucleotides

Volumn 16, Issue 1, 2006, Pages 83-93

  Gekeler, Volker ^a   Gimmnich, Petra ^a   Hofmann, Hans Peter ^a   Grebe, Carola ^a   Römmele, Michaela ^a   Leja, Astrid ^a   Baudler, Monika ^a   Benimetskaya, Luba ^b   Gonser, Barbara ^a   Pieles, Uwe ^c   Maier, Thomas ^a   Wagner, Thomas ^a   Sanders, Karl ^a   Beck, James F ^d   Hanauer, Guido ^a   Stein, C A ^b  

^a ALTANA PHARMA AG   (Germany)

^b ALBERT EINSTEIN CANCER CENTER   (United States)

^c UNIVERSITY OF APPLIED SCIENCES AND ARTS NORTHWESTERN SWITZERLAND   (Switzerland)

^d UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; BIOLOGICAL MARKER; CD19 ANTIGEN; CD86 ANTIGEN; CISPLATIN; CYTOSINE; CYTOTOXIC AGENT; ETOPOSIDE; IMMUNOSTIMULATING AGENT; OBLIMERSEN; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PACLITAXEL; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BCL XS; PROTEIN KINASE C ALPHA; SURVIVIN; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CPG ISLAND; DERIVATIZATION; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TARGETING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; LUNG ADENOCARCINOMA; METHYLATION; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CARCINOMA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIMATE; PRIORITY JOURNAL; SENSITIZATION; SPLEEN; SPLEEN CELL; T LYMPHOCYTE; TISSUE CULTURE; TUMOR CELL; TUMOR MODEL; TUMOR XENOGRAFT;

ANIMALIA; MURINAE; MUS MUSCULUS; PRIMATES; RODENTIA;

EID: 33645822110     PISSN: 15454576     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.2006.16.83     Document Type: Article

References (31)

1. AGRAWAL, S., and KANDIMALLA, R. (2000). Antisense therapeutics: Is it as simple as complementary base recognition? Mol. Med. Today 6, 72-81.
2. AKIRA, S. (2003). Mammalian toll-like receptors. Curr. Opin. Immunol. 15, 5-11.
3. BAINES, J., and CELIS, E. (2003). Immune-mediated tumor regression induced by CpG-containing oligodeoxynucleotides. Clin. Cancer Res. 9, 2693-2700.
4. BALSARI, A., TORTORETO, M., BESUSSO, D., PETRANGOLINI, G., SFONDRINI, L., MAGGI, R., MENARD, S., and PRATESI, G. (2004). Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumor xenografts. Eur. J. Cancer 40, 1275-1281.
5. BENIMETSKAYA, L., WITTENBERGER, T., STEIN, C.A., HOFMANN, H.-P., WELLER, C., LAI, J.C., MILLER, P., and GEKELER, V. (2004). Changes in gene expression induced by phosphorothioate oligodeoxynucleotides (including G3139) in PC3 prostate carcinoma cells are recapitulated at least in part by treatment with interferon-β and -γ. Clin. Cancer Res. 10, 3678-3688.
6. BOONSTRA, A., ASSELIN-PATUREL, C., GILLIET, M., GRAIN, C., TRINCHIERI, G., LIU, Y.J., and O'GARRA, A. (2003). Flexibility of mouse classical and plasmacytoid-derived dendritic cells in directing T helper type 1 and 2 cell development: Dependency on antigen dose and differential toll-like receptor ligation. J. Exp. Med. 197, 101-109.
7. CHI, K.C., WALLIS, A.E., LEE, C.H., DE MENEZES, D.L., SARTOR, J., DRAGOWSKA, W.H., and MAYER, L.D. (2000). Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression. Breast Cancer Res. Treat. 63, 199-212.
8. DEAN, N.M., McKAY, R., CONCON, T.P., and BENNETT, C.F. (1994). Inhibition of protein kinase C-α expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. J. Biol. Chem. 269, 16416-16424.
9. GUVAKOVA, M.A., YAKUBOV, L.A., VLODAVSKY, I., TONKINSON, J.L., and STEIN, C.A. (1995). Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J. Biol. Chem. 270, 2620-2627.
10. HARTMANN, G., WEERATNA, R.D., BALLAS, Z.K., FAYETTE, P., BLACKWELL, S., SUPARTO, I., RASMUSSEN, W.L., WALDSCHMIDT, M., SAJUTHI, D., PURCELL, R.H., DAVIS, H.L., and KRIEG, A.M. (2000). Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune response in vitro and in vivo. J. Immunol. 164, 1617-1624.
11. HECKELSMILLER, K., BECK, S., RALL, K., SIPOS, B., SCHLAMP, A., TUMA, E., ROTHENFUSSER, S., ENDRES, S., and HARTMANN, G. (2002a). Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy. Eur. J. Immunol. 32, 3235-3245.
12. HECKELSMILLER, K., RALL, K., BECK, S., SCHLAMP, A., SEIDERER, J., JARHSDORFER, B., KRUG, A., ROTHENFUSSER, S., ENDRES, S., and HARTMANN, G. (2002b). Peritumoral CpG DNA elicits a coordinated response of CDS T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J. Immunol. 169, 3892-3899.
13. HO, S.P., SCULLY, M.S., KRAUTHAUSER, C.M., WEXLER, E.J., STOW, M.D., DINCHUK, J.E., KERR, J.S., and FRIEDMAN, P.A. (2002). Antisense oligonucleotides selectively regulate aspartyl β-hydroxylase and its truncated protein isoform in vitro but distribute poorly into A549 tumors in vivo. J. Pharmacol. Exp. Ther. 302, 795-803.
14. HORNUNG, V., ROTHENFUSSER, S., BRITSCH, S., KRUG., A., JAHRSDORFER, B., GIESE, T., ENDRES, S., and HARTMANN, G. (2002). Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J. Immunol. 168, 4531-4537.
15. JAHRSDÖRFER, B., JOX, R., MUHLENHOFF, K.L., TSCHOEP, K., KRUG, A., ROTHENFUSSER, S., MEINHARDT, G., EMMERICH, B., ENDRES, S., and HARTMANN, G. (2002). Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN. J. Leukoc. Biol. 72, 83-92.
16. JANSEN, B., WACHECK, V., HEERE-RESS, E., SCHLAGBAUER-WADL, H., HOELLER, C., LUCAS T., HOERMANN, M., HOLLENSTEIN, U., WOLFF, K., and PEHAMBERGER, H. (2000). Chemosensitization of malignant melanoma by BCL2 antisense therapy. Lancet 356, 1728-1733.
17. KHALED, Z., BENIMETSKAYA, L., ZELTSER, R., KHAN, T., SHARMA, H.W., NARAYANAN, R., and STEIN, C.A. (1996). Multiple mechanisms may contribute to the cellular antiadhesive effects of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res. 24, 737-745.
18. KLASA, R.J., GILLUM, A.M., KLEM, R.E., and FRANKEL, S.R. (2002). Oblimersen Bcl-2 antisense: Faciliating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev. 12, 193-213.
19. KRIEG, A. (2001). From bugs to drugs: Therapeutic immunomodulation with oligodesoxynucleotides containing CpG sequences from bacterial DNA. Antisense Nucleic Acid Drug Dev. 11, 181-188.
20. LAI, J.C., BENIMETSKAYA, L., KHVOROVA, A., WU, S., HUA, E., MILLER, P., and STEIN, C.A. (2005). Phosphorothioate oligodeoxynucleotides and G3139 induce apoptosis in 518A melanoma cells. Mol. Cancer Ther. 4, 305-315.
21. LAI, J.C., BENIMETSKAYA, L., SANTELLA, R. M., WANG, Q., MILLER, P.S., and STEIN, C.A. (2003). G3139 (Oblimersen) may inhibit prostate cancer cell growth in a partially bis-CpG-dependent nonantisense manner. Mol. Cancer Ther. 2, 1031-1043.
22. MILAS, L., MASON, K.A., ARIGA, H., HUNTER, N., NEAL, R., VALDECANAS, D., KRIEG, A.M., and WHISNANT, J.K. (2004). CpG oligodeoxynucleotides enhance tumor response to radiation. Cancer Res. 64, 5074-5077.
23. PRATESI, G., PETRANGOLINI, G., TORTORETO, M., ADDIS, A., BELLUCO, S., ROSSINI, A., SELLERI, S., RUMIO, C., MENARD, S., and BALSARI, A. (2005). Therapeutic synergism of gemcitabine and CpG-oligodeoxynucleotides in an orthotopic human pancreatic carcinoma xenograft. Cancer Res. 65, 6388-6393.
24. ROCKWELL, P., O'CONNOR, W., KING, K., GOLDSTEIN, N., ZHANG, L., and STEIN, C.A. (1997). Cell surface pertubations of the EGF and VEGF receptors by phosphorothioate oligonucleotides. Proc. Natl. Acad. Sci. USA 94, 6523-6528.
25. TAMM, I., DÖRKEN, B., and HARTMANN, G. (2001). Antisense therapy in oncology: New hope for an old idea? Lancet 358, 489-497
26. VOLLMER, J., JANOSCH, A., LAUCHT, M., BALLAS, Z.K., SCHETTER, C., and KRIEG, A.M. (2002). Highly immunostimulatory CpG-free oligodeoxynucleotides for activation of human leukocytes. Antisense Nucleic Acid Drug Dev. 12, 165-175.
27. WACHECK, V., KREPLER, C., STROMMER, S., HEEREREES, E., KLEM, R., PEHAMBERGER, H., EICHLER, H.G., and JANSEN, B. (2002). Antitumor effect of G3139 Bcl-2 antisense oligonucleotide is independent of its immune stimulation by CpG motifs in SCID mice. Antisense Nucleic Acid Drug Dev. 12, 359-367.
28. WAGNER, H. (2004). The immunobiology of the TLR9 subfamily. Trends Immunol. 25, 381-386.
29. WEIGEL, B.J., RODEBERG, D.A., KRIEG, A.M., and BLAZAR, B.R. (2003). CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin. Cancer Res. 9, 3105-3114.
30. YAZAKI, T., AHMAD S., CHAHLAVI, A., ZYLBER-KATZ, E., DEAN, N.M., RABKIN, S.D., MARTUZA, R.L., and GLAZER, R.I. (1996). Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-α phosphorothioate oligodeoxynucleotide. Mol. Pharmacol. 50, 236-242.
31. YI, A.K., and KRIEG, A.M. (1998). Rapid induction of mitogen-activated protein kinase by immune stimulatory CpG DNA. J. Immunol. 161, 4493-4497.